Shahram Salek-ardakani - Net Worth and Insider Trading

Shahram Salek-ardakani Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Shahram Salek-ardakani owns 1 companies in total, including Janux Therapeutics Inc (JANX) .

Click here to see the complete history of Shahram Salek-ardakani’s form 4 insider trades.

Insider Ownership Summary of Shahram Salek-ardakani

Ticker	Comapny	Transaction Date	Type of Owner
JANX	Janux Therapeutics Inc	2021-07-12	Chief Scientific Officer

Shahram Salek-ardakani Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Shahram Salek-ardakani Ownership Network

Ownership Network List of Shahram Salek-ardakani

No Data

Ownership Network Relation of Shahram Salek-ardakani

Shahram Salek-ardakani Owned Company Details

What does Janux Therapeutics Inc do?

Who are the key executives at Janux Therapeutics Inc?

Shahram Salek-ardakani is the Chief Scientific Officer of Janux Therapeutics Inc. Other key executives at Janux Therapeutics Inc include director & Chief Executive Officer David Alan Campbell , director & 10 percent owner Ra Capital Healthcare Fund Lp , and 10 percent owner Avalon Ventures Xi, L.p. .

Janux Therapeutics Inc (JANX) Insider Trades Summary

Over the past 18 months, Shahram Salek-ardakani made no insider transaction in Janux Therapeutics Inc (JANX). Other recent insider transactions involving Janux Therapeutics Inc (JANX) include a net sale of 3,324,326 shares made by Avalon Ventures Xi, L.p. , a net sale of 653,961 shares made by Jay Lichter , and a net purchase of 1,695,008 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 2,782,995 shares of Janux Therapeutics Inc (JANX) in total and bought 1,200,000 shares, with a net sale of 1,582,995 shares. During the past 18 months, 6,605,716 shares of Janux Therapeutics Inc (JANX) were sold and 4,244,570 shares were bought by its insiders, resulting in a net sale of 2,361,146 shares.

Janux Therapeutics Inc (JANX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Janux Therapeutics Inc Insider Transactions

No Available Data

Shahram Salek-ardakani Mailing Address

Above is the net worth, insider trading, and ownership report for Shahram Salek-ardakani. You might contact Shahram Salek-ardakani via mailing address: C/o Janux Therapeutics, Inc., 11099 N. Torrey Pines Road, Suite 290, La Jolla Ca 92037.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.